月經治療市場－全球產業規模、佔有率、趨勢、機會與預測：按類型、治療方法、最終用戶、地區和競爭格局分類，2021-2031年

全球月經治療市場預計將從 2025 年的 58.4 億美元大幅成長至 2031 年的 89.7 億美元，複合年成長率為 7.41%。

此市場涵蓋用於緩解月經的藥物和治療方法，主要包括非類固醇消炎劑(NSAIDs)、荷爾蒙避孕藥和用於緩解子宮痙攣的止痛藥。其成長主要受女性健康問題日益增多以及全球醫療保健服務覆蓋範圍擴大的推動。此外，非處方藥的穩定供應確保了持續的需求，為市場擴張奠定了堅實的基礎，使其不受短暫健康趨勢的影響。根據國際疼痛研究協會 (IASP) 估計，到 2025 年，全球月經盛行率將達到約 71.3%，凸顯了有效治療經痛的巨大需求。然而，長期使用藥物治療的副作用，例如抗發炎藥物引起的胃腸道問題，正在顯著阻礙市場成長。這些副作用常導致患者停止治療或猶豫是否繼續長期治療。

市場促進因素

推動市場擴張的主要動力是全球月經的不斷上升。應對這種常見的婦科疾病需要大規模的治療性介入。隨著不同族群中經痛診斷率的增加，需要持續疼痛管理的患者數量龐大，對有效治療方法的需求也持續顯著成長。經痛盛行率的上升也帶來了相當大的經濟負擔，凸顯了提供便捷醫療解決方案的迫切需求。例如，據估計，到2025年，澳洲每年因未治療的月經症狀（包括生產力下降）造成的經濟損失將高達142億美元。如此巨大的經濟影響迫使醫療系統和個人都將有效治療月經作為優先事項。喀麥隆杜阿拉2025年的一項調查進一步凸顯了經痛的廣泛影響，該調查發現，76.5%的受訪少女患有原發性經痛。同時，穿戴式止痛設備的進步正在改變市場格局，為傳統藥物療法提供了非侵入性的替代方案。這直接解決了市場面臨的挑戰，例如長期服用非類固醇消炎劑(NSAIDs) 和口服避孕藥引起的胃腸道問題和荷爾蒙副作用。製造商正在加速開發先進的神經刺激和神經調節穿戴式設備，這些設備能夠阻斷疼痛訊號，從而吸引越來越多注重健康、尋求無藥物替代方案的消費者。這些基於硬體的解決方案正在展現出臨床療效，增強了消費者的信心和接受度。例如，一項於 2025 年 7 月進行的新型神經刺激穿戴裝置的臨床試驗顯示，88% 的參與者表示經期不適有所減輕。因此，朝著檢驗的、技術主導的疼痛管理模式的轉變，正在使市場擺脫對傳統鎮痛藥的依賴，並為該領域的成長開闢新的途徑。

市場挑戰

全球月經治療市場的成長面臨諸多挑戰，其中藥物治療，尤其是長期使用非類固醇消炎劑（NSAIDs）和荷爾蒙避孕藥，其不良副作用尤為突出。雖然這些藥物對於緩解子宮痙攣至關重要，但長期使用往往會導致噁心、消化不良和胃潰瘍等胃腸道問題。這些令人不適的生理反應會直接降低患者對處方治療方案的遵從性，導致治療中斷率居高不下。患者不願繼續服藥會減少重複購買，進而影響對市場永續發展至關重要的收入來源。低依從率造成了潛在患者群體與實際市場規模之間的巨大差距。根據2024年的報告顯示，月經在月經女性的盛行率高達45%至95%，但有效治療方法的普及率仍很低。這一差距表明，儘管這種疾病很普遍，但對藥物副作用的擔憂有效地阻礙了市場滲透，因此，該行業沒有充分利用現有的需求。

市場趨勢

人工智慧驅動的女性健康科技應用正在革新月經疼痛管理。這些應用運用複雜的演算法，提供個人化的症狀緩解和預測資訊。這些平台透過處理使用者提供的數據（例如疼痛程度和月經週期模式），並提案客製化的應對策略，有效地彌合了自我護理和專業醫療建議之間的鴻溝。這項技術進步正在吸引大量投資，凸顯了數據驅動型醫療保健解決方案的商業性可行性，這些解決方案能夠為使用者提供可操作的生殖健康見解。例如，Flo Health 在 2024 年 7 月成功完成 C 輪融資，資金籌措超過 2 億美元，這表明投資者對其專注於生殖健康的個人化數位平台充滿信心。同時，在生物製藥創新領域投資增加的推動下，市場正朝著精準醫療的方向發展，這些創新旨在解決月經疼痛的根本生物學原因。這種從傳統止痛藥轉向精準醫療的趨勢，強調開發旨在最佳化療效並減輕傳統非類固醇抗發炎藥物 (NSAIDs) 常見全身性副作用的特效治療方法。投資正日益轉向這些複雜且有科學根據的治療方法，而非泛泛的健康產品。根據2025年4月的報告，生物製藥產業在女性健康領域的投資在2024年大幅成長至總資金籌措的34%，凸顯了該產業致力於開發標靶治療方案的決心。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球月經治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 類型（原發性經痛，續發性月經）
  • 治療方法（藥物治療、手術、其他療法）
  • 依最終使用者（醫院/診所、門診中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：月經經痛治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲月經治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區月經治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲月經治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲月經治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球月經治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Novartis AG
• Bayer AG
• Abbott Laboratories Inc.
• F Hoffmann-La Roche AG
• Sanofi SA
• Pfizer Inc.
• GSK PLC
• Johnson & Johnson
• Alvogen Inc.
• AbbVie Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The global dysmenorrhea treatment market is projected to expand significantly, rising from USD 5.84 billion in 2025 to USD 8.97 billion by 2031, at a compound annual growth rate (CAGR) of 7.41%. This market involves pharmaceutical and therapeutic methods for easing painful menstruation, predominantly using nonsteroidal anti-inflammatory drugs (NSAIDs), hormonal contraceptives, and analgesics to reduce uterine cramping. Its growth is primarily fueled by the increasing incidence of women's health issues and wider worldwide access to reproductive healthcare. Furthermore, the steady availability of over-the-counter medications ensures consistent demand, forming a robust basis for market expansion separate from fleeting wellness fads.A substantial patient demographic drives this market, with the International Association for the Study of Pain estimating a global dysmenorrhea prevalence of around 71.3% in 2025, underscoring a vast need for effective management. Nevertheless, market growth is significantly hindered by the negative side effects linked to prolonged use of pharmacological treatments, such as the gastrointestinal problems caused by anti-inflammatory drugs, which frequently result in patients discontinuing treatment or being reluctant to commit to long-term regimens.

Market Driver

The primary impetus for market expansion is the escalating global prevalence of dysmenorrhea, which mandates extensive therapeutic intervention to address this widespread gynecological condition. As diagnoses become more frequent across various demographic groups, the sheer volume of individuals needing ongoing pain management generates a significant and sustained demand for efficacious treatments. This rising prevalence also imposes a considerable economic burden, highlighting the urgent need for readily available medical solutions; for example, in 2025, untreated menstrual symptoms, including lost productivity, cost Australia an estimated $14.2 billion annually. Such substantial financial ramifications compel both healthcare systems and individuals to prioritize effective dysmenorrhea management. Further emphasizing the condition's broad impact, a 2025 study in Douala, Cameroon, reported a primary dysmenorrhea prevalence of 76.5% among adolescent girls surveyed.Concurrently, advancements in wearable pain relief devices are transforming the market by introducing non-invasive alternatives to conventional pharmacological approaches. This directly counters the market challenge posed by the adverse gastrointestinal and hormonal effects linked to the long-term use of NSAIDs and oral contraceptives. Manufacturers are increasingly developing advanced neurostimulation and neuromodulation wearables that interrupt pain signals, thereby attracting a growing segment of health-conscious consumers seeking drug-free options. These hardware-based solutions are achieving clinical validation, boosting consumer confidence and adoption. For instance, in July 2025, clinical trials for a new neurostimulation wearable device showed that 88% of participants experienced enhanced menstrual comfort. This movement towards validated, technology-driven pain management diversifies the market beyond standard analgesics and opens new avenues for sector growth.

Market Challenge

The growth of the Global Dysmenorrhea Treatment Market faces a considerable hindrance due to the adverse side effects associated with prolonged use of pharmacological treatments, especially nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal contraceptives. Although these medications are crucial for managing uterine cramping, their extended application often causes gastrointestinal issues like nausea, indigestion, and gastric ulcers. Such uncomfortable physical reactions directly lower patient adherence to prescribed regimens, resulting in high rates of treatment discontinuation. This reluctance to continue medication subsequently decreases repeat purchases and destabilizes the revenue streams vital for sustained market development.This pattern of non-compliance creates a notable discrepancy between the potential patient base and the actual market size. In 2024, the prevalence of dysmenorrhea was reported to range from 45% to 95% among menstruating individuals, yet the uptake of effective treatments remained low. This gap suggests that, despite the widespread nature of the condition, concerns over adverse drug reactions effectively restrict market penetration, thus preventing the industry from fully leveraging the existing demand.

Market Trends

The management of dysmenorrhea is being transformed by the integration of AI-driven femtech applications, which employ sophisticated algorithms to provide personalized symptom relief and predictive information. These platforms process user-submitted data, such as pain levels and menstrual cycle patterns, to suggest customized interventions, effectively bridging the gap between self-care and professional medical advice. This technological advancement is attracting significant investment, affirming the commercial viability of data-focused health solutions that equip users with practical reproductive health insights. For example, in July 2024, Flo Health secured over $200 million in Series C funding, indicating strong investor belief in digital platforms dedicated to personalized reproductive health.Concurrently, the market is moving towards precision medicine, spurred by greater investment in biopharmaceutical innovations that address the underlying biological causes of menstrual pain. This shift from general analgesics emphasizes the creation of specialized therapies aimed at optimizing effectiveness while reducing the systemic side effects commonly linked with traditional NSAIDs. Investment capital is increasingly directed towards these intricate, scientifically supported treatment approaches rather than broader wellness products. According to an April 2025 report, biopharma investment in the women's health sector dramatically increased to 34% of total funding in 2024, underscoring the industry's dedication to developing targeted therapeutic solutions.

Key Market Players

• Novartis AG
• Bayer AG
• Abbott Laboratories Inc.
• F Hoffmann-La Roche AG
• Sanofi SA
• Pfizer Inc.
• GSK PLC
• Johnson & Johnson
• Alvogen Inc.
• AbbVie Inc.

Report Scope

In this report, the Global Dysmenorrhea Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dysmenorrhea Treatment Market, By Type

• Primary Dysmenorrhea
• Secondary Dysmenorrhea

Dysmenorrhea Treatment Market, By Treatment

• Medication
• Surgery
• Therapy

Dysmenorrhea Treatment Market, By End-Users

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Dysmenorrhea Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dysmenorrhea Treatment Market.

Available Customizations:

Global Dysmenorrhea Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dysmenorrhea Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea)
  • 5.2.2. By Treatment (Medication, Surgery, Therapy)
  • 5.2.3. By End-Users (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Dysmenorrhea Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By End-Users
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dysmenorrhea Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End-Users
  • 6.3.2. Canada Dysmenorrhea Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End-Users
  • 6.3.3. Mexico Dysmenorrhea Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End-Users

7. Europe Dysmenorrhea Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By End-Users
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dysmenorrhea Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End-Users
  • 7.3.2. France Dysmenorrhea Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End-Users
  • 7.3.3. United Kingdom Dysmenorrhea Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End-Users
  • 7.3.4. Italy Dysmenorrhea Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By End-Users
  • 7.3.5. Spain Dysmenorrhea Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By End-Users

8. Asia Pacific Dysmenorrhea Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By End-Users
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dysmenorrhea Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End-Users
  • 8.3.2. India Dysmenorrhea Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End-Users
  • 8.3.3. Japan Dysmenorrhea Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End-Users
  • 8.3.4. South Korea Dysmenorrhea Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By End-Users
  • 8.3.5. Australia Dysmenorrhea Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By End-Users

9. Middle East & Africa Dysmenorrhea Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By End-Users
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dysmenorrhea Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End-Users
  • 9.3.2. UAE Dysmenorrhea Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End-Users
  • 9.3.3. South Africa Dysmenorrhea Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End-Users

10. South America Dysmenorrhea Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By End-Users
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dysmenorrhea Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By End-Users
  • 10.3.2. Colombia Dysmenorrhea Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By End-Users
  • 10.3.3. Argentina Dysmenorrhea Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By End-Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dysmenorrhea Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bayer AG
• 15.3. Abbott Laboratories Inc.
• 15.4. F Hoffmann-La Roche AG
• 15.5. Sanofi SA
• 15.6. Pfizer Inc.
• 15.7. GSK PLC
• 15.8. Johnson & Johnson
• 15.9. Alvogen Inc.
• 15.10. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer